NYSE:ABBV
AbbVie Stock News
$166.42
+2.07 (+1.26%)
At Close: May 17, 2024
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
11:46am, Wednesday, 21'st Feb 2024
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira
10:46am, Tuesday, 20'th Feb 2024
AbbVie Inc.'s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company's current president and chief operating officer, Robert Michael.
AbbVie Names New CEO. The Stock's Not Moving.
10:18am, Tuesday, 20'th Feb 2024
Drug maker AbbVie named current President and Chief Operating Officer Robert Michael to succeed Richard Gonzalez as CEO, effective July 1.
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
10:06am, Tuesday, 20'th Feb 2024
Michael, who is AbbVie's chief operating officer, will become the company's second-ever CEO since the company spun out from Abbott Laboratories in 2013.
AbbVie says Richard Gonzalez to step down as CEO
09:28am, Tuesday, 20'th Feb 2024
AbbVie said on Tuesday that Richard Gonzalez will step down from his role as chief executive officer of the drugmaker on July 1.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 19'th Feb 2024
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
3 Cash Cows to Boost Your Confidence During the February Chill
03:20pm, Sunday, 18'th Feb 2024
What are cash cow stocks? If “Jeopardy!
AbbVie Cuts Its Guidance on ImmunoGen Deal
12:20pm, Monday, 12'th Feb 2024
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
07:51am, Monday, 12'th Feb 2024
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The co
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
07:30am, Monday, 12'th Feb 2024
The healthcare industry can be a relatively stable place to invest for generating long-term wealth. AbbVie is dealing with the blow of losing Humira patent exclusivity, but there's more behind the bus
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
08:25am, Sunday, 11'th Feb 2024
AbbVie's next-gen immunology superstars are well on their way to replacing Humira. The company is also an excellent dividend stock.
How I Would Invest $1,000,000 And Live Of Dividends Forever
09:59pm, Saturday, 10'th Feb 2024
Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to plan f
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?
06:18pm, Thursday, 08'th Feb 2024
Investors know the phrase “let your winners run,” but it's easier said than done. The temptation to take profits off the table is often too great to ignore.
5 Dividend Aristocrats Signal Buy In February And 6 To Watch
05:26pm, Wednesday, 07'th Feb 2024
"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represen
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 06'th Feb 2024
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
